UCB (OTCMKTS:UCBJF) Shares Gap Up – Time to Buy?

UCB SA (OTCMKTS:UCBJF)’s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $280.07, but opened at $315.09. UCB shares last traded at $315.09, with a volume of 139 shares traded.

Analysts Set New Price Targets

Several analysts have recently issued reports on UCBJF shares. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of UCB in a research report on Monday, December 8th. Barclays reissued an “overweight” rating on shares of UCB in a report on Tuesday, January 6th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of UCB in a report on Monday, February 16th. Stephens reiterated an “overweight” rating on shares of UCB in a research report on Thursday, January 15th. Finally, Wolfe Research began coverage on UCB in a report on Monday, February 23rd. They set an “outperform” rating on the stock. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of “Buy”.

UCB Stock Down 4.0%

The company has a 50 day simple moving average of $309.69 and a 200-day simple moving average of $283.05. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.